HC Wainwright & Co. Reiterates Buy on Cabaletta Bio, Maintains $30 Price Target

HC Wainwright & Co. analyst Douglas Tsao reiterates Cabaletta Bio (NASDAQ:CABA) with a Buy and maintains $30 price target.

BenzingaMay 16 06:54

Cabaletta Bio's Promising Clinical Advancements and Stable Financial Outlook Merit a Buy Rating

TipRanksMay 15 12:45

William Blair Reaffirms Their Buy Rating on Cabaletta Bio (CABA)

TipRanksMay 15 11:46

NEXTracker Posts Upbeat Earnings, Joins Monday.com, Nu Holdings And Other Big Stocks Moving Higher On Wednesday

U.S. stocks were higher, with the Dow Jones gaining around 150 points on Wednesday.Shares of Nextracker Inc. (NASDAQ:NXT) rose sharply during Wednesday's session after the company reported better-than

BenzingaMay 15 09:21

Cabaletta Bio | 10-Q: Quarterly report

SEC announcementMay 15 06:55 · Announcements

Cabaletta Bio Reveals Insights in Updated Corporate Presentation

TipRanksMay 15 06:22